Paul Clancy
Chairman bij XILIO THERAPEUTICS, INC.
Vermogen: 2 M $ op 31-03-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Jacqualyn Fouse | M | 62 | 7 jaar | |
| Michael Cloonan | M | 53 |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | 15 jaar |
| D. Coward | M | 59 | 9 jaar | |
| Kevin Conroy | M | 58 | 15 jaar | |
| Herve Hoppenot | M | 64 | 10 jaar | |
| Christopher Frankenfield | M | 42 | 3 jaar | |
| Caroline Dorsa | F | 64 | 14 jaar | |
| René Russo | M | 49 | 5 jaar | |
| Adam Rosenberg | M | 54 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | - |
| Michael Dambach | M | 57 |
Stromedix, Inc.
 Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | 17 jaar |
| Daniel Curran | M | 57 | 4 jaar | |
| Julian Baker | M | 57 | 23 jaar | |
| Tomas Jan Heyman | M | 68 | 2 jaar | |
| Shacey Petrovic | F | 50 | 4 jaar | |
| Rahul Ballal | M | 46 | 2 jaar | |
| Sara Bonstein | F | 43 | 3 jaar | |
| Katherine High | M | 72 | 4 jaar | |
| Kathleen Sebelius | F | 74 | 5 jaar | |
| Stephen Sherwin | M | 75 | 14 jaar | |
| Robert Ross | M | 50 | 2 jaar | |
| James Doyle | M | 78 | 10 jaar | |
| James Herriott | M | 44 | 6 jaar | |
| Christina Rossi | F | 48 | 3 jaar | |
| Yuan Xu | M | 56 | 2 jaar | |
| Gianluca Pirozzi | M | 47 | 5 jaar | |
| Cecilia Jones | F | 49 | 2 jaar | |
| Michael Hencke | M | - | 12 jaar | |
| Sarah Gheuens | M | 45 | 5 jaar | |
| Thomas Tray | M | 46 | 19 jaar | |
| Nicole Murphy | F | - | 9 jaar | |
| Kevin Brennan | M | 54 | - | |
| Joshua Resnick | M | 49 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | - |
| Cynthia Smith | F | 55 | 2 jaar | |
| Sheila Denton | F | 58 | 1 jaar | |
| Susan Alexander | F | 67 | 21 jaar | |
| Edmund Harrigan | M | 71 | 5 jaar | |
| Pablo Cagnoni | M | 60 | 1 jaar | |
| Graham Lidgard | M | 75 | 15 jaar | |
| Jeffrey Capello | M | 69 | 1 jaar | |
| Kaye Foster-Cheek | F | 64 | 10 jaar | |
| Eric Rowinsky | M | 67 | 14 jaar | |
| Jorge Garces | M | 52 | 3 jaar | |
| Freda Lewis-Hall | M | 69 | 4 jaar | |
| Daniel Levangie | M | 73 | 14 jaar | |
| Susanne Antonie Schaffert | M | 57 | 2 jaar | |
| Otis Brawley | M | 64 | 3 jaar | |
| Jean-Jacques Bienaimé | M | 70 | 9 jaar | |
| Elena Ridloff | F | 44 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | 8 jaar |
| Pierre Jacquet | M | 57 | 5 jaar | |
| Brian Goff | M | 55 | 2 jaar | |
| May Kin Ho | M | 71 | 9 jaar | |
| David Scadden | M | 71 | 7 jaar | |
| Katherine Zanotti | F | 69 | 15 jaar | |
| Steven Stein | M | 57 | 9 jaar | |
| Denise Brashear | F | - | 2 jaar | |
| Benjamin J. Strain | M | - | 1 jaar | |
| Morry Smulevitz | M | - | 2 jaar | |
| Tamar Thompson | F | 50 | 5 jaar | |
| Tai Yin Yang | M | 70 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | - |
| Lothar H. Finke | M | - | 7 jaar | |
| Paula Swain | F | 66 | 22 jaar | |
| Timothy Scannell | M | 60 | 1 jaar | |
| Peter Langmuir | M | - | 9 jaar | |
| Christiana Stamoulis | F | 53 | 5 jaar | |
| Michael Morrissey | M | - | 8 jaar | |
| Tomasz Beer | M | - | 2 jaar | |
| Lynne Sullivan | M | - |
Stromedix, Inc.
Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | - |
| Vijay Iyengar | M | 51 | 8 jaar | |
| Catalina Loveman | F | - | 9 jaar | |
| Veronica Descotte | F | - | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Paul Friedman | M | 81 | 20 jaar | |
| Aradhana Sarin | M | 50 | - | |
| Kevin Starr | M | 61 | 7 jaar | |
| Marc Tessier-Lavigne | M | 64 | 5 jaar | |
| Michel Vounatsos | M | 62 | 6 jaar | |
| John Maraganore | M | 60 | 13 jaar | |
| Jeffrey Elliott | M | 46 | 8 jaar | |
| Stelios Papadopoulos | M | 74 | 15 jaar | |
| James Mullen | M | 65 | 21 jaar | |
| William Young | M | 79 | 11 jaar | |
| William Rastetter | M | 75 | 19 jaar | |
| Kory Wentworth | M | 45 | 9 jaar | |
| Min Wang | M | - | 8 jaar | |
| Rachel Humphrey | M | 62 | 3 jaar | |
| Glenn Goddard | M | 53 | 6 jaar | |
| Joseph Mara | M | 49 | - | |
| Lewis Cantley | M | 75 | 10 jaar | |
| Michael Wyzga | M | 69 | 6 jaar | |
| Gregory Covino | M | 59 | 6 jaar | |
| Martin Huber | M | 64 | 3 jaar | |
| Richard Mulligan | M | 69 | 14 jaar | |
| Michael Ross | M | 75 | 3 jaar | |
| Daniel Lynch | M | 65 | 2 jaar | |
| Sylvie Grégoire | M | 63 | 8 jaar | |
| Robert Nelsen | M | 60 | 10 jaar | |
| Megan E. Pace | F | 51 | - | |
| Edward C. English | M | 57 | - | |
| Perry Karsen | M | 69 | 5 jaar | |
| Julissa Viana | F | - | - |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 99 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Paul Clancy
- Persoonlijk netwerk
